Benzinga | Jul 20, 2021 07:19AM EDT

SVB Leerink Downgrades Vertex Pharmaceuticals to Underperform, Lowers Price Target to $170

SVB Leerink analyst Geoffrey Porges downgrades Vertex Pharmaceuticals (NASDAQ:VRTX) from Market Perform to Underperform and lowers the price target from $200 to $170.